Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Información
- DOI:
- https://doi.org/10.1002/14651858.CD007695.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 octubre 2009see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Vías respiratorias
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
CJC: Conception of the idea and co‐writing of protocol and review
TL: Co‐writing of the protocol and review
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
NHS R&D, UK.
National Institute of Health Research: Programme Grant
Declarations of interest
None known
Acknowledgements
We acknowledge the assistance of Susan Hansen in obtaining the papers and extracting study details, and of Matthew Cates with the protocol, and for input re physiology of Beta‐agonist receptors. We thank Prof Haydn Walters for providing editorial review and we thank Linda Armstrong from Novartis for providing data on file for Vervloet 1998 and Gabbay 1998, and Joe Gray of AstraZeneca and Dr Everden for clarifying that there were no deaths in Everden 2004.
Version history
| Published | Title | Stage | Authors | Version |
| 2012 Mar 14 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Toby J Lasserson | |
| 2009 Oct 07 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Toby J Lasserson | |
| 2009 Jul 08 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Protocol | Christopher J Cates, Toby J Lasserson | |
Differences between protocol and review
The summary of findings table was not mentioned in the protocol and has been constructed on the basis of the primary outcomes and asthma‐related serious adverse events. Adults and children have been described separately in the summary of findings table.
